Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul-Aug;67(4):479.
doi: 10.4103/ijd.ijd_1074_20.

Mohs Micrographic Surgery for Melanoma: A Convincing Treatment Modality

Stephanie Clements  1 , Amor Khachemoune  2   3
Affiliations

Mohs Micrographic Surgery for Melanoma: A Convincing Treatment Modality

Stephanie Clements et al. Indian J Dermatol. 2022 Jul-Aug.

Abstract

Mohs micrographic surgery (MMS) is the gold standard for treating keratinocyte carcinomas in specific locations or due to other tumor-specific factors, given its comprehensive margin assessment, tissue sparing, and high cure rate. The use of MMS for treating invasive melanoma with intraoperative immunostains is still a subject of debate. Herein, a literature review supports the following recommendations. In cosmetically or functionally demanding sites such as head, neck, hands, feet, and pretibial leg, we recommend MMS for MMIS and all thin melanomas measuring <0.8 mm Breslow depth. Additionally, on the head and neck, all superficial spreading and lentigo maligna melanoma (LMM) histologic subtypes <0.8 mm Breslow depth should be treated with MMS. We recommend using melanoma antigen recognized by T cells 1 (MART-1) immunostain intraoperatively given its high sensitivity. However, microphthalmia transcription factor (MITF) and Sry-related HMG-Box gene 10 (SOX10) are useful adjuncts for difficult cases.

Keywords: Melanocyte; Mohs micrographic surgery; melanoma; tumor progression.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

References

    1. Valentín-Nogueras SM, Brodland DG, Zitelli JA, Gonzalez-Sepulveda L, Nazario CM. Mohsmicrographic surgery using MART-1 immunostain in the treatment of invasive melanoma and melanoma in situ. Dermatol Surg. 2016;42:733–44. - PMC - PubMed
    1. Siscos SM, Neill BC, Seger EW, Hooton TA, Hocker TLH. The current state of Mohssurgery for the treatment of melanoma: A nationwide cross-sectional survey of Mohssurgeons. Dermatol Surg. 2020;46:1267–71. - PubMed
    1. Islami F, Sauer AG, Miller KD, Fedewa SA, Minihan AK, Geller AC, et al. Cutaneous melanomas attributable to ultraviolet radiation exposure by state. Int J Cancer. 2020;147:1385–90. - PubMed
    1. Coit DG, Thompson JA, Albertini MR, Algazi A, Andtbacka R, Barker C, et al. NCCN clinical practice guidelines in oncology: Cutaneous melanoma, version 2.2019. [Last accessed on 2020 Feb 22]. Available from: https://23.nccn.org/professionals/physician_gls/default.aspx .
    1. Rzepecki AK, Hwang CD, Etzkorn JR, Shin TM, Sobanko JF, Howe NM, et al. The “Rule of 10s” versus the “Rule of 2s”: High complication rates after conventional excision with postoperative margin assessment of specialty site versus trunk and proximal extremity melanomas. J Am Acad Dermatol. 2021;85:442–52. - PubMed